Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-12

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit

NCT06251726

Colorectal Cancer

NOT_YET_RECRUITING

Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer

NCT05793775

Metastatic Colorectal Cancer

COMPLETED

Validation of Advanced Colorectal Neoplasm Risk Categories in a Prospective Cohort in Mexico

NCT05661292

Colorectal Cancer Screening

UNKNOWN

Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients

NCT05068531

Colorectal Cancer Metastatic

RECRUITING

Investigation of the Role of the Microbiome in the Pathogenesis of Colorectal Adenoma and Carcinoma

NCT02947607

Colorectal Adenoma and Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Tumor Colon Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female over 18 years old.
* Managed at the CHUGA for a colorectal adenocarcinoma
* With an indication for immediate surgical resection as part of the care.
* Patient naive from neo-adjuvant chemotherapy
* Patient did not object to the CRC-ORGA-2 study

Exclusion Criteria

* Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
* Patients with positive HIV, HBV, HCV serology.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No